Leerink Partners downgraded Metsera Inc (MTSR) to Market Perform from Outperform on September 23, 2025. The current share price stands at $70.50.
This downgrade suggests increased caution regarding Metsera's outlook, potentially reflecting concerns about competitive pressures or market conditions that could impact the company's performance. Metsera, a clinical-stage biopharmaceutical firm based in New York City, focuses on developing innovative peptide therapies for obesity and related conditions. Its advanced product candidate, MET-097i, is a monthly, subcutaneously injectable GLP-1 receptor agonist.
As of November 1, 2025, the analyst consensus for Metsera includes 2 Strong Buy, 4 Buy, 2 Hold, and no Sell or Strong Sell ratings, with an overall consensus rating of Buy. The company's market capitalization is $7.4 billion, and it has an EPS of -3.71. Upcoming earnings reports are expected on May 11, 2026, with an EPS estimate of -0.93, and on March 24, 2026, with an EPS estimate of $0.00.
Analyst ratings and price targets provide insights based on research and financial models. However, they should be considered alongside company fundamentals and market trends when making investment decisions.